Integrum Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Scott Flora

Chief Executive Officer (CEO)

SEK 634.2k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Scott Flora (68 yo)

less than a year

Permanencia

SEK 634,188

Compensación

Mr. Scott D. Flora is the Acting CEO since September 15, 2024 and serves as Director from September 27, 2023 and he previously served as Adjunct Board Member of Integrum AB (publ) since May 11, 2023 until...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Flora	Acting CEO & Director	less than a year	SEK 634.19k	sin datos
Rickard Branemark	Founder	2.5yrs	SEK 2.75m	sin datos
Jorgen Svanstrom	Interim Chief Finance Officer	1.5yrs	sin datos	sin datos
Inger Rydin	Chief Operating Officer	less than a year	sin datos	sin datos
Karin Ganlöv	Chief Medical Officer	2.5yrs	sin datos	sin datos
Jeffrey Zanni	President of U.S. & Head of American Operations	1.3yrs	sin datos	sin datos
Jerry Frimanson	Head of Supply	less than a year	sin datos	sin datos
Anna-Tove Branemark	Chief Executive Officer of Integrum Inc.	no data	sin datos	sin datos

1.3yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6Y1 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Flora	Acting CEO & Director	1.2yrs	SEK 634.19k	sin datos
Rickard Branemark	Founder	no data	SEK 2.75m	sin datos
Bengt Sjoholm	Chairman	5yrs	SEK 346.04k	sin datos
Karin Wingstrand	Director	no data	SEK 173.33k	sin datos
Andrew Christensen	Director	no data	SEK 143.75k	sin datos
Patric Lindgren	Independent Director	4.8yrs	SEK 197.92k	sin datos
Cecilia Wikstrom	Independent Director	4.8yrs	SEK 159.58k	sin datos

4.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 6Y1 se considera experimentada (4.8 años de antigüedad promedio).

Integrum Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum AB (Publ) Announces Management Changes

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

New major risk - Share price stability

Full year 2023 earnings released

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta